Latest Breaking News On - பல்கலைக்கழகம் மருத்துவமனை சிகிச்சையகம் - Page 1 : comparemela.com

May 5, 2021 Novel device designed to address the root cause of mitral regurgitation, avoiding the need for open-heart surgery Company seeks partner to conduct a pivotal study in pursuit of a heart failure indication Clinical data supporting CE Mark to be presented as a late-breaking oral presentation at the virtual AATS 101st annual meeting CARY, N.C., May 5, 2021  Phoenix Cardiac Devices, Inc. announced that it has received CE Mark for its BACE™ (Basal Annuloplasty of the Cardia Externally) device, a novel modality for the treatment of Functional Mitral Regurgitation (FMR). BACE is the only surgical device with long-term clinical data demonstrating significant benefit by addressing the root cause of FMR. The CE Mark serves as approval by the European Union (EU) to commercialize BACE. The supporting clinical data, showing significant efficacy in reduction of MR grade and size of the left ventricle that was sustained out to 24 months

United statesAndhra pradeshJan hlavickaGopal muppiralaPhoenix cardiac devices incUniversity hospital clinic for cardiovascular surgeryPhoenix cardiac incAmerican association for thoracic surgeryChief executive officerPhoenix cardiacUniversity hospital clinicCardiovascular surgeryStatpearls publishingCardiac presents pivotal dataFunctional mitral regurgitationPhoenix cardiac devices